J. Ritter

12.6k citations

205 papers · 9.1k · 2 hit papers · h-index 43

Impact in

Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
Infectious Diseases top 0.5%
- Antifungal resistance and susceptibility

Papers in

Hematology 88
- Acute Myeloid Leukemia Research 76
- Hematopoietic Stem Cell Transplantation 19
- Chronic Myeloid Leukemia Treatments 13
Public Health, Environmental and Occupational Health 71
- Acute Lymphoblastic Leukemia research 69

Co-authors: Stefan Bielack (5 shared papers)Ursula Creutzig (50 shared papers)Alfred Reiter (16 shared papers)G. Schellong (30 shared papers)Martin Schrappe (9 shared papers)Jochen Harbott (19 shared papers)G. Henze (18 shared papers)Helmut Gadner (12 shared papers)
Journals: Blood (9 papers)British Journal of Haematology (5 papers)Journal of Cancer Research and Clinical Oncology (4 papers)Journal of Clinical Oncology (4 papers)European Journal of Cancer (4 papers)
Partner nations: Germany Austria United States

In The Last Decade

J. Ritter

190 papers receiving 8.7k citations

J. Ritter's Hit Papers

align trajectories log scale

Osteosarcoma 2010 · 828 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 Annals of Oncology
2002 Clinical Infectious Diseases

Peers

Countries citing papers authored by J. Ritter

Since Specialization

Citations

This map shows the geographic impact of J. Ritter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Ritter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Ritter more than expected).

Fields of papers citing papers by J. Ritter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Ritter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Ritter. The network helps show where J. Ritter may publish in the future.

Co-authors

The 25 scholars most cited alongside J. Ritter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Ritter Line = papers co-authored together J. Ritter links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 205 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus Clinical Infectious Diseases ·(unknown), John Rex, Ben de Pauw, John E. Bennett, Jacques Billé, F. Crokaert, David W. Denning, J. Peter Donnelly, J. E. Edwards, Z. Erjavec, D Fière, Olivier Lortholary, Johan Maertens, Jacques F. Meis, Thomas F. Patterson, J. Ritter, Dominik Selleslag, P. M. Shah, David A. Stevens, Thomas J. Walsh Hit paper breakdown →	2002	1959
2	Osteosarcoma Annals of Oncology ·J. Ritter, Stefan Bielack Hit paper breakdown →	2010	828
3	Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood ·Martin Schrappe, Alfred Reiter, Wolfgang Ludwig, Jochen Harbott, Martin Zimmermann, Wolfgang Hiddemann, Charlotte M. Niemeyer, Günter Henze, A Feldges, F Zintl, B. Kornhuber, J. Ritter, Karl Welte, Helmut Gadner, Hansjörg Riehm	2000	488
4	Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. Journal of Clinical Oncology ·K. Winkler, G. Beron, G. Delling, U. Heise, H. Kabisch, C. Purfürst, J Berger, J. Ritter, H. Jürgens, V. Gerein	1988	383
5	Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) Klinische Pädiatrie ·H. Riehm, Alfred Reiter, Martin Schrappe, Frank Berthold, R. Dopfer, V. Gerein, R. Ludwig, J. Ritter, B. Stollmann, G. Henze	1987	208
6	Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations European Journal of Cancer ·Joachim Boos, G. Werber, E. Ahlke, P. Schulze-Westhoff, Ulrike Nowak‐Göttl, Gudrun Würthwein, E. J. Verspohl, J. Ritter, H. Jürgens	1996	177
7	Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials Leukemia ·U. Creutzig, M Zimmermann, J. Ritter, Dirk Reinhardt, J Hermann, G. Henze, Heribert Jürgens, H. Kabisch, Alfred Reiter, H. Riehm, Helmut Gadner, G. Schellong, (unknown)	2005	167
8	Improved Treatment Results in High-Risk Pediatric Acute Myeloid Leukemia Patients After Intensification With High-Dose Cytarabine and Mitoxantrone: Results of Study Acute Myeloid Leukemia–Berlin-Frankfurt-Münster 93 Journal of Clinical Oncology ·Ursula Creutzig, J. Ritter, M Zimmermann, Dirk Reinhardt, J Hermann, Frank Berthold, G. Henze, Heribert Jürgens, H. Kabisch, W. Havers, Alfred Reiter, U. Kluba, Felix Niggli, Helmut Gadner, (unknown)	2001	161
9	Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98 Journal of Clinical Oncology ·Ursula Creutzig, Martin Zimmermann, Thomas Lehrnbecher, Norbert Graf, Johann Hermann, Charlotte M. Niemeyer, Alfred Reiter, J. Ritter, Michael Dworzak, Jan Starý, Dirk Reinhardt	2006	147
10	TEL-AML1 Fusion Transcript in Relapsed Childhood Acute Lymphoblastic Leukemia Blood ·K. Seeger, Hans-Peter Adams, Dirk Buchwald, Birgit Beyermann, Bernhard Kremens, Charlotte M. Niemeyer, J. Ritter, Dirk Schwabe, Dörte Harms, Martin Schrappe, Günter Henze	1998	146
11	Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology Haematologica ·Oliver A. Cornely, Angelika Böhme, Dieter Buchheidt, H. Einsele, Werner Heinz, Meinolf Karthaus, Stefan W. Krause, William Krüger, Georg Maschmeyer, Olaf Penack, J. Ritter, Markus Ruhnke, Michael Sandherr, Michal Sieniawski, Jörg Janne Vehreschild, Hans‐Heinrich Wolf, Andrew J. Ullmann	2008	145
12	Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87 Blood ·Ursula Creutzig, Jochen Harbott, Christian Sperling, J. Ritter, M Zimmermann, H. Löffler, H. Riehm, G. Schellong, WD Ludwig	1995	143
13	Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group Blood ·Alfred Reiter, Martin Schrappe, WD Ludwig, F. Lampert, Jochen Harbott, G. Henze, CM Niemeyer, Helmut Gadner, Stefan Müller‐Weihrich, J. Ritter	1992	136
14	Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004 Blood ·Ursula Creutzig, Martin Zimmermann, Jean‐Pierre Bourquin, Michael Dworzak, Gudrun Fleischhack, Norbert Graf, Thomas Klingebiel, Bernhard Kremens, Thomas Lehrnbecher, Christine von Neuhoff, J. Ritter, Annette Sander, André Schrauder, Arend von Stackelberg, Jan Starý, Dirk Reinhardt	2013	134
15	Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86) Cancer ·K. Winkler, Stefan Bielack, G. Delling, M. Salzer‐Kuntschik, R. Kotz, C. Greenshaw, H. Jürgens, J. Ritter, C. Kusnierz-Glaz, R. Erttmann, G. Gädicke, Norbert Graf, Ruth Ladenstein, Serge Leyvraz, R. Mertens, P. Weinel	1990	122
16	Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. PubMed ·Ursula Creutzig, J. Ritter, Josef Vormoor, W. D. Ludwig, Charlotte M. Niemeyer, I. Reinisch, B. Stollmann-Gibbels, Martin Zimmermann, Jochen Harbott	1996	122
17	Definition of a standard‐risk group in children with AML British Journal of Haematology ·Ursula Creutzig, M Zimmermann, J. Ritter, G. Henze, Norbert Graf, H. Löffler, G. Schellong	1999	119
18	Differential pattern of DNA-Aneuploidy in human malignancies Pathology - Research and Practice ·Th. Büchner, Wolfgang Hiddemann, Bernhard Wörmann, B Kleinemeier, J. Schümann, W. Göhde, J. Ritter, K.-M. Müller, DB von Bassewitz, Albert Roessner, E. Grundmann	1985	118
19	Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93 Leukemia ·Ursula Creutzig, J. Ritter, M Zimmermann, J Hermann, Helmut Gadner, D Blütters Sawatzki, CM Niemeyer, Dirk Schwabe, Barbara Selle, Joachim Boos, Joachim Kühl, A Feldges, (unknown)	2001	113
20	Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis Blood ·WD Ludwig, CR Bartram, J. Ritter, A Raghavachar, W Hiddemann, G Heil, J Harbott, H Seibt-Jung, JV Teichmann, H. Riehm	1988	112

About J. Ritter

J. Ritter is a scholar working on Hematology, Public Health, Environmental and Occupational Health, Oncology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 205 papers that have together received 9.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (76 papers), Acute Lymphoblastic Leukemia research (69 papers), Neutropenia and Cancer Infections (29 papers), Hematopoietic Stem Cell Transplantation (19 papers), Sarcoma Diagnosis and Treatment (18 papers), Blood disorders and treatments (15 papers), Neuroblastoma Research and Treatments (13 papers) and Chronic Myeloid Leukemia Treatments (13 papers). The work is most often cited by research in Hematology (2.6k citations), Infectious Diseases (2.0k citations), Public Health, Environmental and Occupational Health (2.6k citations), Oncology (1.4k citations) and Epidemiology (1.6k citations). J. Ritter has collaborated with scholars based in Germany, Austria and United States. Frequent co-authors include Stefan Bielack, Ursula Creutzig, Alfred Reiter, G. Schellong, Martin Schrappe, Jochen Harbott, G. Henze, Helmut Gadner, Thomas F. Patterson and David W. Denning. Their work appears in journals such as Blood, British Journal of Haematology, Journal of Cancer Research and Clinical Oncology, Journal of Clinical Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

J. Ritter

Impact in

Papers in i

In The Last Decade

J. Ritter

J. Ritter's Hit Papers

Peers

Countries citing papers authored by J. Ritter

Fields of papers citing papers by J. Ritter

All Works

About J. Ritter

Explore authors with similar magnitude of impact

Papers in